BLRX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.950

Open

3.600

VWAP

3.73

Vol

106.77K

Mkt Cap

16.45M

Low

3.455

Amount

398.07K

EV/EBITDA(TTM)

--

Total Shares

4.35M

EV

9.32M

EV/OCF(TTM)

--

P/S(TTM)

11.87

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Show More

Events Timeline

(ET)

2026-05-27

07:10:00

Company Reports Q1 Revenue of $0.5M, Achieves Milestone in GLIX1 Clinical Trial

2026-05-19 (ET)

2026-05-19

07:10:00

BioLineRx and Hemispherian Release Encouraging Preclinical Data for GLIX1

2026-04-28 (ET)

2026-04-28

07:10:00

BioLineRx and Hemispherian Initiate GLIX1 Clinical Trial

2026-04-08 (ET)

2026-04-08

05:20:00

Hemispherian Initiates GLIX1 Clinical Trial

2026-03-26 (ET)

2026-03-26

07:10:00

BioLineRx Initiates First-in-Human Study of GLIX1

2026-03-23 (ET)

2026-03-23

07:10:00

BioLineRx to Initiate GLIX1 Clinical Trial by End of Month

2025-11-24 (ET)

2025-11-24

07:04:33

BioLineRx Announces Q3 EPS of 0c, Unchanged from Last Year

2025-09-29 (ET)

2025-09-29

07:06:08

BioLineRx and Hemispherian AS Form Joint Venture for GLIX1 Development

2025-08-14 (ET)

2025-08-14

07:03:01

BioLineRx reports Q2 EPS 0c vs. 0c last year

2025-05-30 (ET)

2025-05-30

08:43:01

BioLineRx upgraded to Buy from Hold at JonesResearch

News

NASDAQ.COM

05-29NASDAQ.COM

BioLineRx (BLRX) Q1 2026 Earnings Transcript

PRnewswire

05-27PRnewswire

BioLineRx Initiates Phase 1/2a Trial for GLIX1 in Glioblastoma

seekingalpha

05-27seekingalpha

BioLineRx Q1 Earnings Exceed Expectations

seekingalpha

05-26seekingalpha

BioLineRx Scheduled to Announce Q1 Earnings

PRnewswire

05-22PRnewswire

BioLineRx and Hemispherian to Present GLIX1 Abstracts at ASCO 2026

Newsfilter

05-22Newsfilter

BioLineRx and Hemispherian Present GLIX1 Research Findings

1 Analyst Rating

Wall Street analysts forecast BLRX stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

No data

No data

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is 93.46, compared to its 5-year average forward P/E of 6.80. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

6.80

Current PE

93.46

Overvalued PE

35.72

Undervalued PE

-22.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.16

Current EV/EBITDA

-0.59

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-2.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

13.56

Current PS

7.55

Overvalued PS

56.51

Undervalued PS

-29.38

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

give me optionable US stock with high ivr

Intellectia · 75 candidates

Region: USIs Optionable: TrueOption Iv Rank: >= 70

Ticker

Name

Market Cap$

ABVC Biopharma Inc

29.64M

Futu Holdings Ltd

17.36B

Hewlett Packard Enterprise Co

49.86B

REE Automotive Ltd

11.80M

ADC Therapeutics SA

431.18M

Okta Inc

16.17B

high growth stocks trading under $5

Intellectia · 184 candidates

Price: <= $5.00Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

10.74M

ReTo Eco-Solutions Inc

2.60M

Iovance Biotherapeutics Inc

1000.00M

Loop Industries Inc

61.87M

Evaxion A/S

26.61M

Onconetix Inc

1.65M

Intellectia · 2866 candidates

Pe Ttm: <= 10

Ticker

Name

Market Cap$

SL Green Realty Corp

3.35B

Avadel Pharmaceuticals PLC

2.11B

HubSpot Inc

15.84B

Arrowhead Pharmaceuticals Inc

9.42B

PDF Solutions Inc

1.42B

Trivago NV

197.86M

Whales Holding BLRX

Trading Trends

People Also Watch

Frequently Asked Questions

What is BioLine RX Ltd (BLRX) stock price today?

The current price of BLRX is 3.78 USD — it has increased 5.29

What is BioLine RX Ltd (BLRX)'s business?

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

What is the price predicton of BLRX Stock?

Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?

BioLine RX Ltd revenue for the last quarter amounts to 194.00K USD, decreased -98.35

What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?

BioLine RX Ltd. EPS for the last quarter amounts to -0.00 USD, decreased

How many employees does BioLine RX Ltd (BLRX). have?

BioLine RX Ltd (BLRX) has 24 emplpoyees as of May 31 2026.

What is BioLine RX Ltd (BLRX) market cap?

Today BLRX has the market capitalization of 16.45M USD.